Abstract: Compounds, compositions and methods for reducing off-target toxicity of T cells expressing a chimeric antigen receptor (CAR-T cells) and/or providing enhanced control of CAR-T cell activation, and methods of treating a subject and/or modifying CAR-T cell activity in a subject with cancer.

Abstract: Compounds, including Toll-like receptor (TLR) agonists, e.g., TLR7 and TLR7/8 agonists and their folic acid or pteroyl amino acid conjugates, and use thereof to treat a cancer or a fibrotic disease or disorder; and methods of making conjugates comprising targeting ligands of folic acid receptor and TLR7 and TLR7/8 agonists.

Abstract: Compounds, pharmaceutical compositions and methods are provided for reprogramming M2-like macrophages to M1-like macrophages, which reverses the antifibrotic to profibrotic shift observed during the course of fibrotic diseases and certain cancers. The compounds comprise an immune modulator that targets a pattern recognition receptor of a cell and are specific to the cells of interest through the incorporation of a targeting moiety (e.g., folate or a functional fragment or analog thereof). Releasable and/or non-releasable linkers can be included and engineered to facilitate the optimal delivery of the immune modulator. The compounds and compositions can be employed in one or more methods of treatment for fibrotic diseases and/or cancers.